Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-09-14
2008-12-09
Fetterolf, Brandon J (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07462595
ABSTRACT:
Methods for treating cancer patients suffering from severe and persistent fatigue, diagnosed as Cancer-Related Fatigue (CRF), with thyrotropin-releasing hormone (TRH) and peptidomimetic analogs of TRH.
REFERENCES:
patent: 3959248 (1976-05-01), Veber et al.
patent: 4059692 (1977-11-01), Takahashi et al.
patent: 4299821 (1981-11-01), Kisfaludy
patent: 4563306 (1986-01-01), Sugano et al.
patent: 4564609 (1986-01-01), Tamura
patent: 4610821 (1986-09-01), Tamura
patent: 4636567 (1987-01-01), Tamura
patent: 4711878 (1987-12-01), Sugano et al.
patent: 4719207 (1988-01-01), Tamura
patent: 4788179 (1988-11-01), Flohe
patent: 4877784 (1989-10-01), Kimura
patent: 4906614 (1990-03-01), Giertz
patent: 4956364 (1990-09-01), Kimura
patent: 5151497 (1992-09-01), Uchida
patent: 5244884 (1993-09-01), Spatola
patent: 5405834 (1995-04-01), Bundgaard
patent: 5686420 (1997-11-01), Faden
patent: 5811512 (1998-09-01), Hirschmann
patent: 5968932 (1999-10-01), Winokur
patent: 6475989 (2002-11-01), Sattin
patent: 6815425 (2004-11-01), Meyerhoff
patent: 7067257 (2006-06-01), Prokai
patent: 2002/0160961 (2002-10-01), Ankersen
patent: 2003/0166944 (2003-09-01), Kelly
Stone (European Journal of Cancer 1998; 34: 1670-1676).
Atkinson et al. (Oncology 2000; 14: 151-161).
Stone et al. (European Journal of Cancer 1998; 34: 1670-1676).
Atkinson, A. et al., NCCN Practice Guidelines for Cancer-Related Fatigue, Oncology, New York, Nov. 2000, vol. 14 (11A Suppl 10), pp. 151-161.
Bower, J. et al., Fatigue in Breast Cancer Survivors: Occurrence, Correlates, and Impact on Quality of Life, Journal of Clinical Oncology, vol. 18, No. 4, Feb. 2000, pp. 743-753.
Bower, J. et al., Fatigue and Proinflammatory Cytokine Activity in Breast Cancer Survivors, Psychosomatic Medicine, vol. 64,No. 4, 2002, pp. 604-611.
Chorvat, R.J. et al., Acetylcholine Release Enhancing Agents: Potential Therapeutics for Alzheimer's Disease, Drugs Future, vol. 20, No. 11, 1995, pp. 1145-1162.
Curt, G. et al., Impact of Cancer-Related Fatigue on the Lives of Patients: New Findings From the Fatigue Coalition, The Oncologist, vol. 5, 2000, pp. 353-360.
De Jong, N. et al., Fatigue in Patients With Breast Cancer Receiving Adjuvant Chemotherapy: A Review of the Literature, Cancer Nursing, vol. 25, No. 4, 2002, pp. 283-297.
Demetri, G. et al., Quality-of-Life Benefit in Chemotherapy Patients Treated With Epoetin Alfa Is Independent of Disease Response or Tumor Type: Results From a Prospective Community Oncology Study, Journal of Clinical Oncology, vol. 16, No. 10, Oct. 1998, pp. 3412-3425.
Dow, K. et al., An evaluation of the quality of life among long-term survivors of breast cancer, Breast Cancer Research and Treatment, vol. 39, 1996, pp. 261-273.
Gary, K. et al., The Thyrotropin-Releasing Hormone (TRH) Hypothesis of Homeostatic Regulation: Implications for TRH-Based Therapeutics, The Journal of Pharmacology and Experimental Therapeutics, vol. 305, No. 2, 2003, pp. 410-416.
Glaus, A. et al., A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals, European Journal of Cancer Care (English language edition), vol. 5, Suppl. 2, 1996, pp. 8-23.
Greenberg, D. et al., Treatment-Related Fatigue and Serum Interleukin-1 Levels in Patients During External Beam Irradiation for Prostate Cancer, Journal of Pain and Symptom Management, vol. 8, No. May 4, 1993, pp. 196-200.
Gutstein, H., The Biologic Basis of Fatigue, 2001 Cancer, vol. 92, No. 6 Suppl., Sep. 15, 2001, pp. 1678-1693.
Holley, S., Cancer-Related Fatigue: Suffering a Different Fatigue, 2000, Cancer Practice, Mar./Apr. 2000, vol. 8, No. 2, pp. 87-94.
Irvine, D. et al., The prevalence and correlates of fatigue in patients receiving treatment with chemotherapy and radiotherapy, Cancer Nursing, vol. 17, 1994, pp. 367-378.
Kunkel, E., et al., Biopsychosocial Aspects of Prostate Cancer, Psychosomatics, vol. 41, No. 2, Mar.-Apr. 2000, pp. 85-94.
Kurzrock, R., The Role of Cytokines in Cancer-Related Fatigue, 2001 Cancer, vol. 92, No. 6 Suppl., Sep. 15, 2001, pp. 1684-1688.
Mendoza, T. et al., The Rapid Assessment of Fatigue Severity in Cancer Patients: Use of the Brief Fatigue Inventory, Cancer, 1999, vol. 85, No. 5, Mar. 1, 1999, pp. 1186-1196.
Mock, V., Fatigue Management: Evidence and Guidelines for Practice, Cancer 2001, vol. 92, No. 6 Suppl., Sep. 15, 2001, pp. 1699-1707.
Portenoy, R. et al., Cancer-Related Fatigue: Guidelines for Evaluation and Management, The Ongologist, vol. 4, 1999, pp. 1-10.
Richardson, A., Fatigue in cancer patients: a review of the literature, European Journal of Cancer Care (English language edition), vol. 4, 1995, pp. 20-32.
Smets, E. et al., The Multidimensional Fatigue Inventory (MFI) Psychometric Qualities of an Instrument to Assess Fatigue, Journal of Psychosomatic Research, vol. 39, No. 5, 1995, pp. 315-325.
Smets, E. et al., Application of the multidimensional fatigue inventory (MFI-20) in cancer patients receiving radiotherapy, British Journal of Cancer, vol. 73, No. 2, 1996, pp. 241-245.
Stone, P. et al., A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer, Ann Oncology, vol. 11, 2000, pp. 561-567.
Stone, P. et al., Fatigue in Patients with Cancer, European Journal of Cancer, vol. 34, No. 11, 1998, pp. 1670-1676.
Valentine, A. et al., Cognitive and Mood Disturbance as Causes and Symptoms of Fatigue in Cancer Patients, Cancer 2001, vol. 92, No. 6 Suppl., Sep. 15, 2001, pp. 1694-1698.
Visser, M. et al., Fatigue, depression and quality of life in cancer patients: how are they related?, Support Care Cancer, vol. 6, 1998, pp. 101-108.
Ware, J. et al., The MOS 36-Item Short-Form Health Survey (SF-36): Conceptual Framework and Item Selection, Medical Care, vol. 30, No. 6, Jun. 1992, pp. 473-483.
WHO Drug Information, vol. 1, No. 3, 1987, pp. 184.
WHO Drug Information, vol. 2, No. 3, 1988, pp. 166.
Yamamura, M. et al., Synthesis and Pharmacological Action of TRH analog peptide (Taltirelin), Nippon Yakurigaku Zasshi, vol. 110, Suppl. 1, 1997, pp. 33P-38P.
Yarbrough, G. et. al., Thyrotropin-releasing hormone (TRH) in the neuroaxis: Therapeutic effects reflect physiological functions and molecular actions, Medical Hypotheses, 2007, pp. 1-8.
Zigmond, A. et al., The Hospital Anxiety and Depression Scale, Acta Psychiatr. Scand., vol. 67, 1983, pp. 361-370.
Prange, Jr. Arthur Jergen
Winokur Andrew
Yarbrough George Gibbs
Fetterolf Brandon J
Savitzky Martin
LandOfFree
Methods for treating cancer-related fatigue does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating cancer-related fatigue, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating cancer-related fatigue will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4030551